
|Videos|March 26, 2018
Would Outcomes-Based Contracting be Beneficial for Orphan Drugs?
Joy Gilbert, Vice President, Operations, US Bioservices, a part of AmerisourceBergen, talks about the potential merits of outcomes-based contracting for drugs that treat rare diseases.
Advertisement
Outcomes-based contracting can be very beneficial for specialty pharmacies, and we certainly have a role to play. We are at the center of the patients care once they leave the physician’s office, particularly with the new oral and self-administered medications.
That being said, there’s only certain factors that as a pharmacy we can control related to those outcomes. So, I think where the value comes into outcomes-based contracting is really helping us as pharmacies show what we can control and how we can impact patient outcomes.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacy Is a Practice, Not Just a Place
2
Beat the Heat: 10 Common Medication Culprits Causing Heat Intolerance
3
Yes, COVID-19 Is Still a Big Deal. Pharmacy Is the Tip of the Spear (and Needle)
4
FDA Fast Tracks First-in-Class TNFR2 Antibody as Chemotherapy-Free Strategy for Platinum-Resistant Ovarian Cancer
5




































































































